AONM WEBINAR SERIES

DISCLAIMER: THIS SITE DOES NOT PROVIDE MEDICAL ADVICE

The information on this webpage and these webinars is intended for educational and informative purposes only and is not intended as a substitute for medical or professional advice, diagnosis or treatment. Always seek the advice of your doctor or other qualified health care provider with regards to any questions you may have regarding a medical condition or treatment before undertaking a health care regimen. Never disregard or delay seeking professional medical advice because of information you have read or seen on this website. The opinions stated in these webinars are those of the people speaking and not necessarily of AONM.

See also www.nhs-corona-doctors-on-the-frontline.com/

Dr. Schwarzbach discusses the important and underrecognised links between infections and hypercoagulation (“sticky blood”), mast cell overreactivity (mast cell activation syndrome is one name for this – MCAS). Dr. Schwarzbach specialises in testing for tick-borne infections, but he will also be covering a wider range of pathogens, including viruses.

Prof. Dr. Med. Katharina Pachmann discusses the methods that her laboratory uses, and their findings.

PROF. DR. MED. KATHARINA PACHMANN is the founder of the Maintrac system of identifying circulating cancer cells in a “liquid biopsy”, and runs the Maintrac laboratory in Bayreuth, Germany, together with Dr. Ulrich Pachmann and a staff of 45. As both a medical doctor and research scientist, she has been conducting studies in this field and refining related techniques for over two decades, and has authored over a hundred scientific publications on the technique (https://aonm.org/scientific-articles-and-studies/)

She received her PhD from the Institute for Haematology at the Society for Radiological Research, Munich, and worked as the Head of the Department of Experimental Haematology and Oncology, Friedrich Schiller-University, Jena, for many years. She is a visiting scientist at the University Clinic, Graz, Austria, and has also served in the same capacity at MD Anderson Cancer Center Houston Texas Section of Molecular Hematology and Therapy.

Dr. Craig D. Shimasaki, PhD, MBA is President & CEO Moleculera Labs, Inc.

PANS and PANDAS are infection-induced autoimmune conditions that disrupt a patient’s normal neurologic functioning. PANS and PANDAS can include a variety of symptoms, such as OCD, motor tics, anxiety, irritability, hyperactivity, sleep disturbances, mood swings, depression, hyperactivity, difficulty concentrating, behavioural regression and urinary problems. This condition can exist in adults too, not just children.

This is the second of three webinars on this topic. In the first webinar Dr. Shimasaki explains the background to the Cunningham Panel and indications for its use. To view the first webinar see below or follow this link https://aonm.org/view-past-webinars/

In this second webinar Dr. Shimasaki will focus on how to interpret the findings, including new study results that substantiate correlations between results and patient symptoms/outcomes.

Moleculera Labs is the only lab in the world to test for autoimmune activity against neuronal targets in the brain that is used by clinics/practitioners across the world to identify encephalitic-type activity called “PANS/PANDAS” in children, and autoimmune encephalopathy in adults. It is characterised by many symptoms that are often considered psychiatric and not given any further biomedical exploration.

Dr. Craig D. Shimasaki, PhD, MBA is President & CEO Moleculera Labs, Inc.

Moleculera Labs is the only lab in the world to test for autoimmune activity against neuronal targets in the brain that is used by clinics/practitioners across the world to identify encephalitic-type activity called “PANS/PANDAS” in children, and autoimmune encephalopathy in adults. It is characterised by many symptoms that are often considered psychiatric and not given any further biomedical exploration. He will explain the use of the Cunningham Panel, how to interpret the results, and its application in therapy. This will be the first of three webinars on this topic

Dr Shimisaki is a scientist with over 33 years of clinical diagnostic and therapeutic R&D experience, starting his career at Genentech. During his tenure he has been involved in the research, development and clinical testing of neuropsychiatric drugs and diagnostics, genetic testing for predisposition to non-familial breast cancer, a gp-120 HIV vaccine, and influenza and RSV diagnostics and therapeutics. He co-founded Moleculera Labs with Dr. Madeleine Cunningham, an autoimmune neurobiology clinical laboratory based upon her 20+ years of research on infection-triggered autoimmune disorders.

His focus has been to translate basic research discoveries into acutely needed medical products for patients who need them. He has led five clinical diagnostic tests through FDA approval process and is a co-inventor on several medical and diagnostic patents. Dr. Shimasaki is an Adjunct Professor at the University of Oklahoma. He has authored and edited two books “The Business of Bioscience: What Goes Into Making a Biotechnology Product” and “Biotechnology Entrepreneurship: Starting, Managing and Leading Biotech Companies.” He received his BS in Biochemistry from University of California at Davis, his PhD in Molecular Biology from the University of Tulsa, and his MBA from Northwestern University, Kellogg School of Business.

Dr. Schwarzbach is Founder and Medical Director at ArminLabs, Augsburg, Germany.

He presented evidence of the different bacterial and viral infections that can lead to syndromes that are often labelled unexplained or psychiatric in nature, and gave insights from his three decades of experience in this field. He explains algorithims for deciding which to test for, and also answered a number of questions in a live Q&A.
Please see https://aonm.org/armin-labs/ for background information on this lab and its tests.

As a Medical Doctor and specialist in laboratory medicine with three decades of experience in clinical medicine and laboratory testing, Dr. Schwarzbach specialises in laboratory medicine in infectiology, microbiology, immunology, hematology, clinical chemistry, endocrinology and gynecological endocrinology.

Professor Dr. med. Katharina Pachmann is the founder of the Maintrac system of identifying circulating cancer cells in a “liquid biopsy”, and runs the Maintrac laboratory in Bayreuth, Germany, together with Dr. Ulrich Pachmann and a staff of 45.

Professor Katharina Pachmann explained how the Maintrac test in Germany tests for circulating cancer cells, the circumstances within which it may be appropriate to use it, and how it tests for the effectiveness of chemotherapeutic as well as natural agents. Please see https://aonm.org/maintrac/

As both a medical doctor and research scientist, she has been conducting studies in this field and refining related techniques for over two decades, and has authored over a hundred scientific publications on the technique (https://aonm.org/scientific-articles-and-studies/).

She received her PhD from the Institute for Haematology at the Society for Radiological Research, Munich, and worked as the Head of the Department of Experimental Haematology and Oncology, Friedrich Schiller-University, Jena, for many years. She is a visiting scientist at the University Clinic, Graz, Austria, and has also served in the same capacity at MD Anderson Cancer Center Houston Texas Section of Molecular Hematology and Therapy.